Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima,Manish A. Shah,Kei Muro,Eric Francois,Antoine Adenis,Chih-Hung Hsu,Toshihiko Doi,Toshikazu Moriwaki,Sung-Bae Kim,Se-Hoon Lee,Jaafar Bennouna,Ken Kato,Lin Shen,Peter C. Enzinger,Shukui Qin,Paula Ferreira,Jia Chen,Gustavo Colagiovanni Girotto,Christelle De La Fouchardiere,Hélène Senellart,Raed Al-Rajabi,Florian Lordick,Ruixue Wang,Shailaja Suryawanshi,P Bhagia,S. Peter Kang,Jean-Philippe Metges,Keynote Investigators

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

2020

PURPOSEPatients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy.PATIENTS AND METHODSIn this open-label, phase III study, we randoml...

Keywords:

Oncology
Internal medicine
Pembrolizumab
MEDLINE
poor prognosis
Chemotherapy
treatment options
advanced esophageal cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

123

Citations